The FDA plans to conduct two studies to gauge whether consumers and healthcare professionals have the capacity to detect and report deceptive prescription drug advertisements.

The proposed studies would evaluate how consumers and healthcare professionals respond to targeted advertisements that consist of varying degrees and types of deception.

The first study, which will enroll a total of 750 participants, focuses on whether healthcare professionals and consumers can recognize deceptive advertisements in egregious and subtle cases. The second study, which will also enlist 750 participants, will consider implicit versus explicit deception.